Your browser doesn't support javascript.
loading
Alternative Treatment with Every-Other-Day Dosing of Sunitinib for Metastatic Renal Cell Carcinoma: Extended Follow-Up.
Ohba, Kojiro; Miyata, Yasuyoshi; Mitsunari, Kensuke; Matsuda, Tsuyoshi; Mukae, Yuta; Nakamura, Yuichiro; Matsuo, Tomohiro; Sakai, Hideki.
Affiliation
  • Ohba K; Department of Urology and Renal Transplantation, Nagasaki University Hospital, Nagasaki, Japan.
  • Miyata Y; Department of Urology and Renal Transplantation, Nagasaki University Hospital, Nagasaki, Japan.
  • Mitsunari K; Department of Urology and Renal Transplantation, Nagasaki University Hospital, Nagasaki, Japan.
  • Matsuda T; Department of Urology and Renal Transplantation, Nagasaki University Hospital, Nagasaki, Japan.
  • Mukae Y; Department of Urology, Nagasaki Harbor Medical Center, 6-39 Shinchimachi, Nagasaki, Japan.
  • Nakamura Y; Department of Urology and Renal Transplantation, Nagasaki University Hospital, Nagasaki, Japan.
  • Matsuo T; Department of Urology and Renal Transplantation, Nagasaki University Hospital, Nagasaki, Japan.
  • Sakai H; Department of Urology and Renal Transplantation, Nagasaki University Hospital, Nagasaki, Japan.
Urol Int ; 106(6): 623-629, 2022.
Article in En | MEDLINE | ID: mdl-35045411
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Kidney Neoplasms / Antineoplastic Agents Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Urol Int Year: 2022 Type: Article Affiliation country: Japan
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Kidney Neoplasms / Antineoplastic Agents Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Urol Int Year: 2022 Type: Article Affiliation country: Japan